Neuroblastoma medical therapy

Jump to navigation Jump to search

Neuroblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neuroblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neuroblastoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neuroblastoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neuroblastoma medical therapy

CDC on Neuroblastoma medical therapy

Neuroblastoma medical therapy in the news

Blogs on Neuroblastoma medical therapy

Directions to Hospitals Treating Neuroblastoma

Risk calculators and risk factors for Neuroblastoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]

Overview

Children oncology group (COG) risk stratification system determines the protocol of management used for neuroblastoma patients. COG risk stratification system divides the patients into 03 groups: low risk, intermediate risk and high risk patients. Low risk neuroblastoma patients are usually managed by either observation or surgical resection of the tumor. Intermediate risk patients are managed by neoadjuvant therapy in advance of a definitive surgical resection. High risk neuroblastoma patients are usually managed by a combination of surgery, chemotherapy, radiation therapy, hematopoietic stem cell transplantation, immunotherapy and isotretrinoin.

Medical Therapy

Risk Stratification[1][2][3][4]


 
 
 
 
 
Children's Oncology Group risk stratification
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low risk patients
 
Intermediate risk patients
 
High risk patients
 
 
 
 
 
 
 
 
 


Management of Low Risk Neuroblastoma Patients[5][6][7]

Observation

Radiotherapy

Chemotherapy

Management of Intermediate Risk Neuroblastoma Patients[5][8]

Observation

  • Observation is generally not recommended for the management of intermediate risk neuroblastoma patients.

Radiotherapy

  • Indications for radiotherapy for the management of intermediate risk neuroblastoma patients include:

Chemotherapy

Management of High Risk Neuroblastoma Patients[5][9][10]

Observation

  • Observation is generally not recommended for the management of high risk neuroblastoma patients.

Radiotherapy

Chemotherapy

  • Induction therapy:
  • Consolidation therapy:
  • Maintenance therapy:

References

  1. Chizuko Okamatsu, Wendy B. London, Arlene Naranjo, Michael D. Hogarty, Julie M. Gastier-Foster, A. Thomas Look, Michael LaQuaglia, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Robert C. Seeger, Tsutomu Saji & Hiroyuki Shimada (2009). "Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG". Pediatric blood & cancer. 53 (4): 563–569. doi:10.1002/pbc.22106. PMID 19530234. Unknown parameter |month= ignored (help)
  2. Susan L. Cohn, Andrew D. J. Pearson, Wendy B. London, Tom Monclair, Peter F. Ambros, Garrett M. Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin, Veronique Mosseri, Thorsten Simon, Alberto Garaventa, Victoria Castel & Katherine K. Matthay (2009). "The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (2): 289–297. doi:10.1200/JCO.2008.16.6785. PMID 19047291. Unknown parameter |month= ignored (help)
  3. Chrystal U. Louis & Jason M. Shohet (2015). "Neuroblastoma: molecular pathogenesis and therapy". Annual review of medicine. 66: 49–63. doi:10.1146/annurev-med-011514-023121. PMID 25386934.
  4. Andrew M. Davidoff (2012). "Neuroblastoma". Seminars in pediatric surgery. 21 (1): 2–14. doi:10.1053/j.sempedsurg.2011.10.009. PMID 22248965. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 5.2 5.3 Neuroblastoma treatment–for health professionals. National Cancer Institute (2015) http://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq#section/_1 Accessed on October, 8 2015
  6. Jed G. Nuchtern, Wendy B. London, Carol E. Barnewolt, Arlene Naranjo, Patrick W. McGrady, James D. Geiger, Lisa Diller, Mary Lou Schmidt, John M. Maris, Susan L. Cohn & Robert C. Shamberger (2012). "A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study". Annals of surgery. 256 (4): 573–580. doi:10.1097/SLA.0b013e31826cbbbd. PMID 22964741. Unknown parameter |month= ignored (help)
  7. Douglas R. Strother, Wendy B. London, Mary Lou Schmidt, Garrett M. Brodeur, Hiroyuki Shimada, Paul Thorner, Margaret H. Collins, Edward Tagge, Stanton Adkins, C. Patrick Reynolds, Kevin Murray, Robert S. Lavey, Katherine K. Matthay, Robert Castleberry, John M. Maris & Susan L. Cohn (2012). "Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30 (15): 1842–1848. doi:10.1200/JCO.2011.37.9990. PMID 22529259. Unknown parameter |month= ignored (help)
  8. David L. Baker, Mary L. Schmidt, Susan L. Cohn, John M. Maris, Wendy B. London, Allen Buxton, Daniel Stram, Robert P. Castleberry, Hiroyuki Shimada, Anthony Sandler, Robert C. Shamberger, A. Thomas Look, C. Patrick Reynolds, Robert C. Seeger & Katherine K. Matthay (2010). "Outcome after reduced chemotherapy for intermediate-risk neuroblastoma". The New England journal of medicine. 363 (14): 1313–1323. doi:10.1056/NEJMoa1001527. PMID 20879880. Unknown parameter |month= ignored (help)
  9. Valeria Smith & Jennifer Foster (2018). "High-Risk Neuroblastoma Treatment Review". Children (Basel, Switzerland). 5 (9). doi:10.3390/children5090114. PMID 30154341. Unknown parameter |month= ignored (help)
  10. K. Beiske, S. A. Burchill, I. Y. Cheung, E. Hiyama, R. C. Seeger, S. L. Cohn, A. D. J. Pearson & K. K. Matthay (2009). "Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force". British journal of cancer. 100 (10): 1627–1637. doi:10.1038/sj.bjc.6605029. PMID 19401690. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources